Equities Analysts Issue Forecasts for CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATXFree Report) – Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Perspective Therapeutics in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($0.90) for the year, up from their prior estimate of ($0.95). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.86) per share.

Perspective Therapeutics (NYSE:CATXGet Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%.

A number of other research firms also recently weighed in on CATX. Bank of America started coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Royal Bank of Canada reduced their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Wedbush restated an “outperform” rating and issued a $20.00 target price on shares of Perspective Therapeutics in a research note on Thursday, October 24th. UBS Group initiated coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Finally, Truist Financial assumed coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Perspective Therapeutics currently has an average rating of “Buy” and an average target price of $21.57.

Check Out Our Latest Analysis on CATX

Perspective Therapeutics Price Performance

NYSE CATX opened at $6.78 on Monday. Perspective Therapeutics has a 52-week low of $2.28 and a 52-week high of $19.05. The stock’s 50-day moving average is $12.37.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CATX. Bleakley Financial Group LLC purchased a new stake in Perspective Therapeutics in the first quarter valued at approximately $40,000. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $57,000. US Bancorp DE raised its position in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Perspective Therapeutics in the 2nd quarter worth approximately $117,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth approximately $118,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Featured Stories

Earnings History and Estimates for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.